JP2022105084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022105084A5 JP2022105084A5 JP2022072043A JP2022072043A JP2022105084A5 JP 2022105084 A5 JP2022105084 A5 JP 2022105084A5 JP 2022072043 A JP2022072043 A JP 2022072043A JP 2022072043 A JP2022072043 A JP 2022072043A JP 2022105084 A5 JP2022105084 A5 JP 2022105084A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- acid sequence
- amino acid
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 9
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 4
- 208000037908 antibody-mediated disorder Diseases 0.000 claims 4
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000000779 depleting effect Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 239000004606 Fillers/Extenders Substances 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 2
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims 2
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000008822 Ankylosis Diseases 0.000 claims 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000001930 Autoimmune limbic encephalitis Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100027221 CD81 antigen Human genes 0.000 claims 1
- 102100027217 CD82 antigen Human genes 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 208000031976 Channelopathies Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 claims 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010023198 Joint ankylosis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100025574 Leukocyte immunoglobulin-like receptor subfamily A member 5 Human genes 0.000 claims 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 claims 1
- 206010024434 Lichen sclerosus Diseases 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000017281 Morvan syndrome Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 208000025174 PANDAS Diseases 0.000 claims 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 102100029216 SLAM family member 5 Human genes 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000006424 autoimmune oophoritis Diseases 0.000 claims 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims 1
- 208000029407 autoimmune urticaria Diseases 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 229960001838 canakinumab Drugs 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000004379 membrane Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023209102A JP2024037846A (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130076P | 2015-03-09 | 2015-03-09 | |
| US62/130,076 | 2015-03-09 | ||
| JP2022051047A JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022051047A Division JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023209102A Division JP2024037846A (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022105084A JP2022105084A (ja) | 2022-07-12 |
| JP2022105084A5 true JP2022105084A5 (cg-RX-API-DMAC7.html) | 2022-11-22 |
| JP7403575B2 JP7403575B2 (ja) | 2023-12-22 |
Family
ID=55863122
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547456A Pending JP2018509413A (ja) | 2015-03-09 | 2016-03-08 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2021016293A Active JP7050191B2 (ja) | 2015-03-09 | 2021-02-04 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022051047A Active JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022072043A Active JP7403575B2 (ja) | 2015-03-09 | 2022-04-26 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2023209102A Pending JP2024037846A (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547456A Pending JP2018509413A (ja) | 2015-03-09 | 2016-03-08 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2021016293A Active JP7050191B2 (ja) | 2015-03-09 | 2021-02-04 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
| JP2022051047A Active JP7391132B2 (ja) | 2015-03-09 | 2022-03-28 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023209102A Pending JP2024037846A (ja) | 2015-03-09 | 2023-12-12 | ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20160264669A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4006051A1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2018509413A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102720769B1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016230827B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2978253A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3268391T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA038178B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2882999T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE056775T2 (cg-RX-API-DMAC7.html) |
| IL (2) | IL254403B (cg-RX-API-DMAC7.html) |
| LT (1) | LT3268391T (cg-RX-API-DMAC7.html) |
| MX (2) | MX386491B (cg-RX-API-DMAC7.html) |
| MY (1) | MY188761A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3268391T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3268391T (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201908259WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016142782A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202109042B (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3087095T3 (da) | 2013-12-24 | 2019-10-28 | Argenx Bvba | FcRn-antagonist og fremgangsmåder til anvendelse |
| SG11201705475QA (en) * | 2015-01-30 | 2017-08-30 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| AU2016230827B2 (en) * | 2015-03-09 | 2021-10-28 | argenx BV | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| AU2018380979B2 (en) * | 2017-12-08 | 2023-07-20 | argenx BV | Use of FcRn antagonists for treatment of generalized myasthenia gravis |
| MX2020013195A (es) | 2018-06-08 | 2021-02-26 | Argenx Bvba | Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria. |
| US20220081481A1 (en) * | 2019-01-16 | 2022-03-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease |
| GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2021014756A (es) * | 2019-06-07 | 2022-01-18 | Argenx Bvba | Formulaciones farmaceuticas de inhibidores de fcrn adecuadas para administracion subcutanea. |
| MX2022001038A (es) * | 2019-07-25 | 2022-04-26 | Genzyme Corp | Métodos para tratar trastornos mediados por anticuerpos con antagonistas de fcrn. |
| CN115836086A (zh) | 2020-01-08 | 2023-03-21 | 阿尔金克斯有限公司 | 治疗天疱疮病症的方法 |
| CN114341184B (zh) * | 2020-02-10 | 2023-04-04 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
| WO2021252917A2 (en) | 2020-06-11 | 2021-12-16 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2021257668A1 (en) * | 2020-06-17 | 2021-12-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of gene therapy patients |
| KR20240036076A (ko) * | 2021-08-13 | 2024-03-19 | 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 | Fcrn을 특이적으로 인식하는 항체 및 이의 용도 |
| AU2023290529A1 (en) | 2022-06-15 | 2024-12-12 | argenx BV | Fcrn/antigen-binding molecules and methods of use |
| JP2025537777A (ja) * | 2022-11-14 | 2025-11-20 | アルジェニクス ビーブイ | ＦｃＲｎアンタゴニスト分子及びそれらの使用方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6128119A (en) | 1997-01-10 | 2000-10-03 | Asahi Kogaku Kogyo Kabushiki Kaisha | Beam shaping optical system |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
| US7091321B2 (en) | 2000-02-11 | 2006-08-15 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6992234B2 (en) * | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
| WO2002040047A2 (en) | 2000-11-20 | 2002-05-23 | Canadian Blood Services | Method for treating thrombocytopenia with monoclonal ivig |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
| EP2298805A3 (en) | 2002-09-27 | 2011-04-13 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| EP2272533A1 (en) | 2003-01-13 | 2011-01-12 | MacroGenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| EP1896503B1 (en) * | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| AU2008254951A1 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto |
| TWI504409B (zh) * | 2009-03-25 | 2015-10-21 | Genentech Inc | 新穎抗－α５β１抗體及其用途 |
| CA2837184C (en) * | 2011-05-25 | 2021-09-21 | Innate Pharma, S.A. | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders |
| CA2853637C (en) * | 2011-10-26 | 2023-04-04 | Novartis Ag | Anti-canine cd20 monoclonal antibodies and methods of use |
| WO2013074598A1 (en) * | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING |
| JP6285923B2 (ja) * | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用 |
| DK3087095T3 (da) * | 2013-12-24 | 2019-10-28 | Argenx Bvba | FcRn-antagonist og fremgangsmåder til anvendelse |
| AU2016230827B2 (en) * | 2015-03-09 | 2021-10-28 | argenx BV | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
-
2016
- 2016-03-08 AU AU2016230827A patent/AU2016230827B2/en active Active
- 2016-03-08 EA EA201791984A patent/EA038178B1/ru unknown
- 2016-03-08 HU HUE16719896A patent/HUE056775T2/hu unknown
- 2016-03-08 JP JP2017547456A patent/JP2018509413A/ja active Pending
- 2016-03-08 PT PT167198969T patent/PT3268391T/pt unknown
- 2016-03-08 US US15/064,195 patent/US20160264669A1/en active Pending
- 2016-03-08 CA CA2978253A patent/CA2978253A1/en active Pending
- 2016-03-08 ES ES16719896T patent/ES2882999T3/es active Active
- 2016-03-08 SG SG10201908259W patent/SG10201908259WA/en unknown
- 2016-03-08 LT LTEPPCT/IB2016/000398T patent/LT3268391T/lt unknown
- 2016-03-08 MX MX2017011534A patent/MX386491B/es unknown
- 2016-03-08 EP EP21189336.7A patent/EP4006051A1/en active Pending
- 2016-03-08 WO PCT/IB2016/000398 patent/WO2016142782A1/en not_active Ceased
- 2016-03-08 KR KR1020177027256A patent/KR102720769B1/ko active Active
- 2016-03-08 IL IL254403A patent/IL254403B/en unknown
- 2016-03-08 MY MYPI2017001178A patent/MY188761A/en unknown
- 2016-03-08 IL IL295425A patent/IL295425A/en unknown
- 2016-03-08 EP EP16719896.9A patent/EP3268391B1/en active Active
- 2016-03-08 PL PL16719896T patent/PL3268391T3/pl unknown
- 2016-03-08 DK DK16719896.9T patent/DK3268391T3/da active
- 2016-03-08 SG SG11201707053SA patent/SG11201707053SA/en unknown
-
2017
- 2017-09-08 MX MX2021011633A patent/MX2021011633A/es unknown
-
2021
- 2021-02-04 JP JP2021016293A patent/JP7050191B2/ja active Active
- 2021-11-15 ZA ZA2021/09042A patent/ZA202109042B/en unknown
- 2021-12-02 AU AU2021277720A patent/AU2021277720B2/en active Active
-
2022
- 2022-03-28 JP JP2022051047A patent/JP7391132B2/ja active Active
- 2022-04-26 JP JP2022072043A patent/JP7403575B2/ja active Active
-
2023
- 2023-12-12 JP JP2023209102A patent/JP2024037846A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022105084A5 (cg-RX-API-DMAC7.html) | ||
| JP2017501725A5 (cg-RX-API-DMAC7.html) | ||
| JP2018509413A5 (cg-RX-API-DMAC7.html) | ||
| ES2823950T3 (es) | Moléculas con especificidad para CD45 y CD79 | |
| JP2016527187A5 (cg-RX-API-DMAC7.html) | ||
| CA3258002A1 (en) | FCRN BINDING MOLECULES AND METHODS OF USE | |
| CA3034480A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| US20080227704A1 (en) | CXCL13 binding proteins | |
| JP2014520092A5 (cg-RX-API-DMAC7.html) | ||
| CN112154156A (zh) | 抗cd38抗体的皮下给药 | |
| JP2018522578A (ja) | ヒト化型親和性成熟抗ＦｃＲｎ抗体 | |
| JPH1087510A (ja) | ナイトロジェンマスタード系抗癌剤と組合わせて使用するための骨髄腫治療剤 | |
| JP2018524007A (ja) | Ｃｄ２２に結合する抗体分子 | |
| WO2010055366A4 (en) | Anti-human il-21 monoclonal antibodies | |
| JP2018529313A (ja) | Ｃｄ７９に結合する抗体分子 | |
| CA2734645A1 (en) | Engineered anti-il-13 antibodies, compositions, methods and uses | |
| HK1207870A1 (en) | Anti-human sema4a antibodies useful to treat disease | |
| JPWO2020004490A5 (cg-RX-API-DMAC7.html) | ||
| TW201619197A (zh) | 新穎抗人類Ｉｇβ抗體 | |
| CN113660952A (zh) | 双特异性抗体 | |
| CA3237268A1 (en) | Human tumor necrosis factor alpha antibodies | |
| NZ773089B2 (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| NZ773089A (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| JPWO2023242372A5 (cg-RX-API-DMAC7.html) | ||
| NZ734416A (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |